Calcium and Magnesium and Potassium and Sodium Oxybate
Brand names: Xywav · Active ingredient: Sodium Oxybate, Calcium Oxybate, Potassium Oxybate
In short: XYWAV is indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy. XYWAV is indicated for the treatment of idiopathic hypersomnia (IH) in adults.
What is Calcium and Magnesium and Potassium and Sodium Oxybate used for?
XYWAV is indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy.
XYWAV is indicated for the treatment of idiopathic hypersomnia (IH) in adults.
⚠ Boxed warning (FDA's strongest warning)
•
Central Nervous System Depression
XYWAV is a CNS depressant. Clinically significant respiratory depression and obtundation may occur in patients treated with XYWAV at recommended doses . Many patients who received XYWAV during clinical trials in narcolepsy and idiopathic hypersomnia were receiving central nervous system stimulants .
•
Abuse and Misuse
The active moiety of XYWAV is oxybate or gamma-hydroxybutyrate (GHB). Abuse or misuse of illicit GHB, either alone or in combination with other CNS depressants, is associated with CNS adverse reactions, including seizure, respiratory depression, decreases in the level of consciousness, coma, and death .
Because of the risks of CNS depression and abuse and misuse, XYWAV is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the XYWAV and XYREM REMS .
Calcium and Magnesium and Potassium and Sodium Oxybate dosage
The recommended starting dosage is 4.5 grams (g) per night administered orally, divided into two doses: 2.25 g at bedtime and 2.25 g taken 2.5 to 4 hours later . Increase the dosage by up to 1.5 g per night per week (e.g., 0.75 g at bedtime and 0.75 g taken 2.5 to 4 hours later), to the recommended dosage range of 6 g to 9 g per night. The dosage may be gradually titrated based on efficacy and tolerability. Some patients may achieve better responses with unequal doses at bedtime and 2.5 to 4 hours later. Doses higher than 9 g per night have not been studied and ordinarily should not be administered.
Note: Some patients may achieve better responses with unequal nightly doses at bedtime and 2.5 to 4 hours later.
If a Patient’s Total Nightly Dosage Is: | Take at Bedtime: | Take 2.5 to 4 Hours Later:
4.5 g per night | 2.25 g | 2.25 g
6 g per night | 3 g | 3 g
7.5 g per night | 3.75 g | 3.75 g
9 g per night | 4.5 g | 4.5 g
For pediatric patients 7 years of age and older, XYWAV is administered orally twice per night. The recommended starting pediatric dosage, titration regimen, and maximum total nightly dosage are based on patient weight, as specified in Table 2. The dosage may be gradually titrated based on efficacy and tolerability. Doses higher than 9 g per night have not been studied and ordinarily should not be administered.
* For patients who sleep more than 8 hours per night, the first nightly dose of XYWAV may be given at bedtime or after an initial period of sleep.** If XYWAV is used in patients 7 years of age and older who weigh less than 20 kg, a lower starting dosage, lower maximum weekly dosage increases, and lower total maximum nightly dosage should be considered.Note: Some patients may achieve better responses with unequal nightly doses at bedtime and 2.5 to 4 hours later.
Patient Weight | Initial Dosage | Maximum Weekly Dosage Increase | Maximum Recommended Dosage
Take at Bedtime: | Take 2.5 to 4 Hours Later: | Take at Bedtime: | Take 2.5 to 4 Hours Later: | Take at Bedtime: | Take 2.5 to 4 Hours Later:
<20 kg** | There is insufficient information to provide specific dosing recommendations for patients who weigh less than 20 kg.
20 kg to <30 kg | ≤1 g | ≤1 g | 0.5 g | 0.5 g | 3 g | 3 g
30 kg to <45 kg | ≤1.5 g | ≤1.5 g | 0.5 g | 0.5 g | 3.75 g | 3.75 g
≥45 kg | ≤2.25 g | ≤2.25 g | 0.75 g | 0.75 g | 4.5 g | 4.5 g
The dosage and regimen of XYWAV should be individualized based on clinical presentation .
XYWAV can be administered as a twice nightly or once nightly regimen. The recommended starting dose, titration guidance, and maximum nightly doses appear in Table 3:
* Some patients may achieve better responses with unequal nightly doses at bedtime and 2.5 to 4 hours later. …
How to take Calcium and Magnesium and Potassium and Sodium Oxybate — instructions & advice from the label
Advise the patient and/or caregiver to read the FDA-approved patient labeling (Medication Guide and Instructions for Use).
Central Nervous System Depression
Inform patients and/or caregivers that XYWAV can cause central nervous system depression, including respiratory depression, hypotension, profound sedation, syncope, and death. Instruct patients not to engage in activities requiring mental alertness or motor coordination, including operating hazardous machinery, for at least 6 hours after taking XYWAV. Instruct patients and/or their caregivers to inform their healthcare providers of all the medications they take .
Abuse and Misuse
Inform patients and/or caregivers that the active ingredient of XYWAV is gamma-hydroxybutyrate (GHB), which is associated with serious adverse reactions with illicit use and abuse .
XYWAV and XYREM REMS
XYWAV is available only through a restricted program called the XYWAV and XYREM REMS . …
Warnings & precautions
Do not take this medicine if: XYWAV is contraindicated for use in:
•combination with sedative hypnotics .
•combination with alcohol .
•patients with succinic semialdehyde dehydrogenase deficiency .
XYWAV is a central nervous system (CNS) depressant. Clinically significant respiratory depression and obtundation has occurred in adult patients taking sodium oxybate (same active moiety as XYWAV) at recommended doses in clinical trials and may occur in patients treated with XYWAV at recommended doses. XYWAV is contraindicated in combination with alcohol and sedative hypnotics. The concurrent use of XYWAV with other CNS depressants, including but not limited to opioid analgesics, benzodiazepines, sedating antidepressants or antipsychotics, sedating anti-epileptic drugs, general anesthetics, muscle relaxants, and/or illicit CNS depressants, may increase the risk of respiratory depression, hypotension, profound sedation, syncope, and death.
If use of these CNS depressants in combination with XYWAV is required, dose reduction or discontinuation of one or more CNS depressants (including XYWAV) should be considered. In addition, if short-term use of an opioid (e.g., post- or perioperative) is required, interruption of treatment with XYWAV should be considered.
Healthcare providers should caution patients about operating hazardous machinery, including automobiles or airplanes, until they are reasonably certain that XYWAV does not affect them adversely (e.g., impair judgment, thinking, or motor skills). Patients should not engage in hazardous occupations or activities requiring complete mental alertness or motor coordination, such as operating machinery or a motor vehicle or flying an airplane, for at least 6 hours after taking XYWAV. Patients should be queried about CNS depression‐related events upon initiation of XYWAV therapy and periodically thereafter. …
Calcium and Magnesium and Potassium and Sodium Oxybate side effects
The following clinically significant adverse reactions appear in other sections of the labeling:
•CNS depression
•Abuse and Misuse
•Respiratory Depression and Sleep-Disordered Breathing
•Depression and Suicidality
•Other Behavioral or Psychiatric Adverse Reactions
•Parasomnias
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
Adult Patients with Narcolepsy
The safety of XYWAV was evaluated in a 16‑week double-blind placebo-controlled randomized-withdrawal study in patients with narcolepsy with cataplexy (Study 1), which was followed by an open-label extension phase lasting 24 weeks . Study 1 included an open‑label titration period (OL OTTP), a stable-dose period (SDP), and a double‑blind, placebo‑controlled, randomized-withdrawal period (DB RWP). A total of 201 patients, ages 18 to 70 years, received XYWAV at individually titrated doses for 14 weeks, followed by randomization to XYWAV or matching placebo for 2 weeks of treatment. The mean exposure to XYWAV during this study, including titration, the randomized withdrawal period, and the open-label extension, was 151 days. In patients who remained on treatment, adverse reactions tended to occur early and diminish over time. …
Drug interactions
XYWAV is contraindicated for use in combination with alcohol or sedative hypnotics. Use of other CNS depressants may potentiate the CNS-depressant effects of XYWAV .
Concomitant use of sodium oxybate with divalproex sodium results in an increase in systemic exposure to GHB, which was shown to cause a greater impairment on some tests of attention and working memory in a clinical study . A similar increase in exposure is expected with concomitant use of XYWAV and divalproex sodium; therefore, an initial dose reduction of XYWAV is recommended when used concomitantly with divalproex sodium . Prescribers are advised to monitor patient response closely and adjust dose accordingly if concomitant use of XYWAV and divalproex sodium is warranted.
About this medicine
XYWAV oral solution contains oxybate, a CNS depressant. The chemical name of oxybate is gamma-hydroxybutyrate (GHB). XYWAV contains a mixture of calcium oxybate, magnesium oxybate, potassium oxybate, and sodium oxybate equivalent to 0.5 g/mL, which corresponds to 0.413 g/mL oxybate.
Each mL of XYWAV contains: 0.234 g calcium oxybate, Ca(C4H7O3)2; 0.096 g magnesium oxybate, Mg(C4H7O3)2; 0.13 g potassium oxybate, K(C4H7O3); and 0.04 g sodium oxybate, Na(C4H7O3) in dissociated form in the solution. The molecular weights of each are as follows: calcium oxybate is 246.3, magnesium oxybate is 230.5, potassium oxybate is 142.2, and sodium oxybate is 126.1.
The chemical structure is:
y=1 for Na+ and K+; y=2 for Mg2+ and Ca2+
The inactive ingredients are purified water and sucralose. XYWAV contains no ingredient made from a gluten‑containing grain (wheat, barley, or rye).
How it works: XYWAV is a CNS depressant. The exact mechanism of action of XYWAV in the treatment of narcolepsy and idiopathic hypersomnia is unknown. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 1e0ae43a-037f-42af-8e23-a0e51d75abe8. Read the full official label on DailyMed.
Related medicines
Tirzepatide Buspirone Venlafaxine Zolpidem Citalopram Lorazepam Temazepam Melatonin